Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

March 9, 2018: By Joan McKenna

Okogen announced Feb. 27 that it raised $10 million in a Series A financing to advance OKG-0301, its lead candidate for viral conjunctivitis (pink eye).

The San Diego-based company describes OKG-0301 as an ophthalmic formulation of ranpirnase, a potent ribonuclease with established broad-spectrum antiviral properties.

Brian M. Strem, CEO, said the funding would support initiation of a Phase II clinical trial before the end of 2018.

The company’s focus is on infectious ocular diseases where treatments are either not available or unsatisfactory. A second targeted disease is cytomegalovirus retinitis.

Brandon Capital’s Medical Research Commercialisation Fund, a collaboration between Australian pension funds, research institutes, and the Australian and New Zealand governments, provided the funding.

Okogen also announced the appointment of Quinton Oswald to the firm’s board. Oswald is president and CEO of Notal Vision. Previously, he was president and CEO at Neurotech Pharmaceuticals and SARcode Bioscience. Oswald also held executive level roles at Genentech, Novartis, and Bristol-Myers Squibb.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023